These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23560831)

  • 1. Cancer therapy: could a novel test predict the amount of drug that reaches its target?
    van der Veldt AA; Smit EF; Lammertsma AA
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):377-9. PubMed ID: 23560831
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody positron emission tomography imaging in anticancer drug development.
    Lamberts LE; Williams SP; Terwisscha van Scheltinga AG; Lub-de Hooge MN; Schröder CP; Gietema JA; Brouwers AH; de Vries EG
    J Clin Oncol; 2015 May; 33(13):1491-504. PubMed ID: 25779566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis.
    Lim EH; Danthi N; Bednarski M; Li KC
    Nanomedicine; 2005 Jun; 1(2):110-4. PubMed ID: 17292065
    [No Abstract]   [Full Text] [Related]  

  • 4. [Handling the therapeutic response from the tumor with PET].
    Baena Cañada JM
    Rev Esp Med Nucl; 2010; 29(5):273-4. PubMed ID: 20675018
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical molecular imaging with positron emission tomography.
    Saleem A; Charnley N; Price P
    Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.
    Quarles van Ufford HM; van Tinteren H; Stroobants SG; Riphagen II; Hoekstra OS
    J Nucl Med; 2010 Oct; 51(10):1507-16. PubMed ID: 20847179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From bedding to bedside: genetically engineered mouse models of cancer inform concurrent clinical trials.
    Damsky WE; Bosenberg M
    Pigment Cell Melanoma Res; 2012 Jul; 25(4):404-5. PubMed ID: 22578163
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of molecular imaging in modern drug development.
    Cunha L; Szigeti K; Mathé D; Metello LF
    Drug Discov Today; 2014 Jul; 19(7):936-48. PubMed ID: 24434047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography as an imaging biomarker.
    Weber WA
    J Clin Oncol; 2006 Jul; 24(20):3282-92. PubMed ID: 16829652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
    Antunes IF; Haisma HJ; de Vries EF
    Nucl Med Commun; 2008 Oct; 29(10):845-6. PubMed ID: 18769302
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of PET for monitoring cancer therapy and for predicting outcome.
    Weber WA
    J Nucl Med; 2005 Jun; 46(6):983-95. PubMed ID: 15937310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of PET/CT in the development of novel anticancer drugs.
    Boss DS; Olmos RV; Sinaasappel M; Beijnen JH; Schellens JH
    Oncologist; 2008 Jan; 13(1):25-38. PubMed ID: 18245010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET Center - Masaryk Memorial Cancer Institute, Brno, Czech Republic.
    Bolcák K
    Nucl Med Rev Cent East Eur; 2005; 8(2):160-2. PubMed ID: 16437408
    [No Abstract]   [Full Text] [Related]  

  • 14. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMS and PET for solid tumors.
    Cannon H
    J Nucl Med; 2008 Dec; 49(12):23N. PubMed ID: 19038994
    [No Abstract]   [Full Text] [Related]  

  • 16. 99mTc sestamibi and 99mTc tetrofosmin scintigraphy for predicting resistance to chemotherapy: a critical review of clinical data.
    Van de Wiele C; Rottey S; Goethals I; Buscombe J; Van Belle S; De Vos F; Dierckx RA
    Nucl Med Commun; 2003 Sep; 24(9):945-50. PubMed ID: 12960592
    [No Abstract]   [Full Text] [Related]  

  • 17. Positron emission tomography: current status and future challenges.
    Lin M; Shon IH; Lin P
    Intern Med J; 2010 Jan; 40(1):19-29. PubMed ID: 20561362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on criteria for assessing tumor response to treatment.
    Cruite I; Osman S; Dighe M
    Curr Probl Diagn Radiol; 2013; 42(5):209-19. PubMed ID: 24070714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 4.
    Eccles SA
    IDrugs; 2007 Dec; 10(12):844-7. PubMed ID: 18041676
    [No Abstract]   [Full Text] [Related]  

  • 20. Noninvasive positron emission tomography imaging of cell death using a novel small-molecule probe, (18)F labeled bis(zinc(II)-dipicolylamine) complex.
    Wang H; Tang X; Tang G; Huang T; Liang X; Hu K; Deng H; Yi C; Shi X; Wu K
    Apoptosis; 2013 Aug; 18(8):1017-27. PubMed ID: 23613106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.